On September 5, 2019 KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co. being held September 8-10, 2019, at the Lotte New York Palace Hotel (Press release, KemPharm, SEP 5, 2019, http://investors.kempharm.com/news-releases/news-release-details/kempharm-present-21st-annual-global-investment-conference [SID1234539312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of KemPharm’s presentation are as follows:

Event: 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
Date: Monday, September 9, 2019
Time: 2:35 PM ET
Location: Lotte New York Palace Hotel, New York, NY
The presentation will be webcast and available on the Investor Relations section of the Company’s website at View Source

On September 5, 2019 Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, reported that Kirk Look, Chief Financial Officer of Oncolytics Biotech, will present at the H.C. Wainwright 21st Annual Global Investment Conference at 5:30 pm Eastern Time on Monday, September 9, 2019 (Press release, Oncolytics Biotech, SEP 5, 2019, View Source [SID1234539311]). The conference is being held September 8-10, 2019 at the Lotte New York Palace Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio link to the webcast session will be available on the Company’s website at View Source It is recommended that listeners log on 10 minutes in advance of the live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.

On September 5, 2019 VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that Jeff Baxter, President and CEO, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York City on Tuesday, September 10, 2019, at 8:20 AM ET (Press release, VBI Vaccines, SEP 5, 2019, View Source [SID1234539310]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

- Event: H.C. Wainwright 21st Annual Global Investment Conference
- Date: Tuesday, September 10, 2019
- Time: 8:20 – 8:45 AM ET
- Webcast: View Source

A live webcast of the presentation may also be accessed by visiting the Investors page of VBI’s website at www.vbivaccines.com.

On September 5, 2019 Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, reported its participation in the following industry conferences in September (Press release, Unum Therapeutics, SEP 5, 2019, View Source [SID1234539309]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell & Gene Therapy Bioprocessing & Commercialization, September 9 – 12, Boston, MA.

Geoffrey Hodge, Chief Technical Officer at Unum Therapeutics, will present "Designing the Cell Therapy Facility of the Future by Learning from the Past" on Tuesday, September 10, 2019 at 8:40 a.m. ET.
CAR-TCR Summit, September 10 – 13, Boston, MA.

David O’Donnell, Director, Technology Operations at Unum Therapeutics, will present "Managing Leukapheresis for Autologous Cell Therapies" on Tuesday, September 10, 2019 at 9:00 a.m. ET.

Ann Ranger, Ph.D., Senior Director, Translational Medicine and Biomarkers at Unum Therapeutics, will present "Clinical Pharmacology of a Unique Antibody Coupled T Cell (ACTR) Therapy Combination Product" on Thursday, September 12, 2019 at 1:00 p.m. ET.
2nd International Conference on Lymphocyte Engineering (ICLE), September 13 – 15, London, UK.

Seth Ettenberg, Ph.D., Chief Scientific Officer at Unum Therapeutics, will present "Addressing the Challenges of T Cell Therapies in Solid Tumors" on Friday, September 13, 2019 at 6:50 p.m. BST / 1:50 p.m. EDT in London, United Kingdom.

On September 5, 2019 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that the company is scheduled to present at the following upcoming investor conference (Press release, Trillium Therapeutics, SEP 5, 2019, View Source [SID1234539308]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 21st Annual Global Investment Conference
Presenter: Dr. Bob Uger, Chief Scientific Officer and Interim President
Date and Time: September 10, 2019 at 4:40 p.m. ET
Location: Lotte New York Palace Hotel, New York City

A live audio webcast of the H.C. Wainwright 21st Annual Global Investment Conference presentation will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com.